AllDocs -> cancers

U-266 Cell line U-266, human myeloma Transfection with Plasmid pEGFP-C1 (in bidistilled H 2 O) Electroporation buffer Eppendorf Hypoosmolar Electroporation Buffer (PH) Culture medium IMDM / 10 % FCS Cuvette Eppendorf, 2 mm gap width, 400 µl Temperature RT (20-25 °C) Reference Frau Pfeifer Universitätsklinikum Leipzig Molekulare Immunologie Johannisallee 30 D-04103 Leipzig Phone: +49 341 9725494 Fax: +49 341 9725489 1. Harvest the cells in the exponential growth phase and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). 2. Resuspend the cells in IMDM / 0.5% FCS, determine the number of cells and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). Remove supernatant. Note: The overall incubation time in the Eppendorf Electroporation Buffer must not exceed 30 minutes to guarantee a successful electroporation! ...

1998 1999 2001 2000 Fiscal Year Milli on s o f D ollar s $10.8M 2002 $18.0M 0 2003 $15.3M $26.3M i 5 10 15 20 30 $20.8M 25 $19.7M Incidence and Mortality Rate Trends Myeloma , also known as multiple myeloma or plasma cell myeloma , is the second most common blood cancer, and comprises approximately one percent of all cancers. Unfortunately, there has been little change in the overall incidence rate of myeloma , and the mortality rate has increased over the past three decades. The incidence rate is higher in men than women. Myeloma is more common among the elderly, and African Americans have approximately double the incidence and mortality rates of Whites. ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? MARCH NOTES Meeting: Tuesday March 16, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: Group Discussion / Minneapolis Seminar Acupuncture for Myeloma Patients - Kevin Clark More Information: Chuck Koval ...

MULTIPLE MYELOMA AND OTHER PLASMA CELL DYSCRASIAS 713 CHAPTER 33 Multiple myeloma and other plasma cell dyscrasias Raman Desikan, MD , Sundar Jagannath, MD , Paul Richardson, MD , and Nikhil C. Munshi, MD MULTIPLE MYELOMA Multiple myeloma is a disseminated malignancy of monoclonal plasma cells that accounts for 8% of all hematologic cancers. In the year 2003, an estimated 14,600 new cases will be diagnosed in the United States, and 10,900 Ameri- cans will die of this disease. Incidence rates for myeloma (5.3 in men and 3.5 in women) and mortality rates (3.7 in men and 2.5 in women) per 100,000 popu- lation have remained stable for the past decade. Epidemiology Gender Males are affected more frequently than females (1.4:1.0 ratio). Age The median age at presentation ...

laboratorymedicine> may 2003> number 5> volume 34 357 © case study [ chemistry | hematology] Pseudohyponatremia in a Myeloma Patient: Direct Electrode Potentiometry is a Method Worth its Salt Andrew W. Lyon, PhD, Leland B. Baskin, MD Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, Alberta, Canada DOI: 10.1309/1LND9XBND712PP0Q Patient 49-year-old Caucasian male. Chief Complaint He presented to our cancer clinic complaining of malaise, tired- ness, and bone pain. Prior Medical History The patient had a 4-year history of progressive multiple myeloma (IgG-lambda immunophenotype) with gradually increasing bone pain that was refractory to high dose chemotherapy and autologous stem cell transplantation. He had been treated recently with morphine, a bisphosphonate ...

March/April 2004, Vol. 11, No. 2 Cancer Control 119 No significant relationship exists between the author and the compa- nies/organizations whose products or services may be referenced in this article. Stem Cell Transplantation for Multiple Myeloma Cristina Gasparetto, MD Background: Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients in the United State per year. The median overall survival is 5 years, and cure is a realistic goal for only a small minority of patients. Methods: A review of the literature was conducted that focused on treatment strategies for MM involving administration of high doses of chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplant. Results: For over three decades, the standard treatment for MM has been a regimen of melphalan and prednisone ...

myeloma MYELOMA AND THE KIDNEY DIAGNOSIS TREATMENT PROGNOSIS MYELOMA Monoclonal expansion of plasma cell population Incidence ~5 per 100,000 Median age 69 male, 71 female 5% <40 years at diagnosis; 10-15% <50 years Diagnostic Criteria 1 MAJOR plasmacytoma on tissue biopsy bone marrow plasmacytosis >30% monoclonal globulin elevation on electrophoresis >35 ...

[CANCER RESEARCH 63, 6689 – 6696, October 15, 2003] Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/ NOD in Vivo Model: Biologic and Clinical Implications 1 Constantine S. Mitsiades, 2, 3 Nicholas S. Mitsiades, 3 Ron T. Bronson, Dharminder Chauhan, Nikhil Munshi, Steven P. Treon, Christopher A. Maxwell, Linda Pilarski, Teru Hideshima, Robert M. Hoffman, and Kenneth C. Anderson 2 Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115 [C. S. M., N. S. M., D. C., N. M., S. P. T., T. H., K. C. A.]; Departments of Medicine [C. S. M., N. S. M., D. C., N. M., S. P. T., T. H., K. C. A.] and Pathology [R. T. B.], Harvard Medical School, Boston, Massachusetts 02115; Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2 Canada ...

Leukemia (2002) 16 , 1664–1667 2002 Nature Publishing Group All rights reserved 0887-6924/02 $25.00 www.nature.com/leu Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells S Le Gouill 1 , C Pellat-Deceunynck 1 , J-L Harousseau 3 , M-J Rapp 3 , N Robillard 2 , R Bataille 1 , and M Amiot 1 1 Institut National de la Sante´ et de la Recherche Me´dicale Unite´ 463, Institut de Biologie, Nantes, France; 2 Service d’He´matologie Biologique, Nantes, France and 3 Service d’He´matologie Clinique, Nantes, France R115777, a nonpeptidomimetic farnesyl transferase inhibitor has recently demonstrated a significant antileukemic activity in vivo in acute myeloid leukemia. Multiple myeloma (MM) is a fatal hematological ...

myeloma Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin ( M protein ) Incidence: 3 - 9 cases per 100000 population / year more frequent in elderly modest male predominance Multiple Myeloma Clinical forms: multiple myeloma solitary plasmacytoma plasma cell leukemia M protein: ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? FEBRUARY NOTES Meeting: Tuesday February 17, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: Myeloma Update: IMF Seminar of January 23 - 25 Mayo Clinic Research Conference of February 5 - 7 &...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORTGROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? JANUARY NEWSLETTER Meeting: Tuesday, January 20, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: Focus on Caregivers More Information: Chuck Koval Jane Buffett &n...

MULTIPLE MYELOMA MULTIPLE MYELOMA Myelomagenesis > > > Progression Overexpressed Genes Myeloma -specific Chromosomal Translocations Cytokines and Their Receptors Various clinical manifestations Bone Lesion Hyperproteinemia Bone Marrow Failure Immunodeficiency Hyperammonemia Hyperamylasemia Others MYELOMA CELLS STROMAL CELLS Cytokines Angiogenic Factors Signal Transduction Anti-myelomatous Agents Chemotherapeutic Agents Thalidomide ATRA Arsenic Acid Statins Vit K 2 bisphosphonates Others Immunomodulation Dendritic Cells T-cells Apoptosis-inducing Cells Surface Markers Stem Cell Transplantation Page 2 Cyclin D1 FGFR3 Cyclin D3 c-maf MUM1/IRF4 ...

. Your Treatment Team Your Treatment Team L E A D I N G T H E S E A R C H F O R A C A N C E R C U R E Sylvester Comprehensive Cancer Center 1475 NW 12th Avenue • Miami, Florida 33136 305-243-1000 1-800-545-2292 www.sylvester.org An Equal Opportunity/Affirmative Action University . Leukemia, Lymphoma, and Myeloma UM/Sylvester’s leukemia, lymphoma, and myeloma treatment team includes highly trained hematologist/oncologists and radiation oncologists, all widely recognized for their work in the field. The team is supported by a group of basic science and clinical researchers who work diligently to learn more about these diseases—their detection and treatment, as well as options to improve each patient’s quality of life. As is true with all cancer specialties at ...

Phone 818 452 CURE (2873) Fax 818 487 7454 E-mail TheIMF@ myeloma .org Web www. myeloma .org International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607-3421 www. myeloma .org “Today there is so much information available about myeloma and that’s good.” “But how do I make sense of it all?” “How do I know what’s right for me?” The International Myeloma Foundation can help! To learn what the latest advances in myeloma treatment and management mean for you - attend the International Myeloma Foundation’s Minneapolis Patient & Family Seminar Radisson Hotel Metrodome March 12 – 13, 2004 To register go to www. myeloma .org or contact Paul Hewitt at the IMF 800 452 CURE (2873) You’ll meet world-renowned myeloma ...

Myeloma Cell Line Preparation Introduction Several different mouse and human myeloma cell lines are available for use in hybridoma formation. However, only a very few are used frequently. The mouse myeloma cell line that is used most often is the same one we will be using in this course. It is designated: P3x63,Ag8.653 ( ATCC CRL-1580 ) Although some specially designed lines are used for unique applications, this line has been used for years to produce most of the monoclonal antibodies used in clinical and research applications. Thus, we are using this cell line to give you experience in handling the line that you are likely to encounter if you do this type of work in Co-op or after graduation. This cell line is a non-secretor (i.e., does not produce antibodies on its own), is 8- azaguanine resistant (important during selection of hybridoma cells), is derived from the ...

Mouse Myeloma Cell Line myeloma - tumor of cell that originates in bone marrow rapid cell division acclimated to tissue culture conditions (cell line) tissue culture medium used Dulbecco's Modified Eagle's Medium (DMEM) with glucose supplement 10-15% serum supplement (growth factors, nutrients) fetal bovine (best and most expensive) newborn calf (less expensive, but doesn't work with our cell line) calf (OK for most of the routine culturing of our cell line) antibiotics & antimycotics 5% CO 2 , 37 o C, humidity suspension culture (non-adherent) generally forms irregular clumps of cells cells will look almost spherical "cobblestone" appearance of cells that form monolayers directly on flask surface Myeloma cell line used in this course P3x63,Ag8.653 mouse myeloma cell ( ATCC ...

2004 Multiple Myeloma Presidents: Mario Boccadoro Alessandro Pileri April 22-24, 2004 TORINO Centro Congressi Lingotto PROGRAM PROGRAM Page 2 SCIENTIFIC SECRETARIAT Benedetto Bruno Massimo Massaia Paola Omedè Antonio Palumbo Divisione Universitaria di Ematologia Ospedale San Giovanni Battista di Torino Via Genova 3 - 10126 Torino - Italy mario.boccadoro@unito.it ORGANIZING SECRETARIAT Studio E.R. Congressi - Gruppo Triumph via Marconi 36 - 40122 Bologna - Italy Phone +39 051 4210559 Fax +39 051 4210174 e-mail: ercongressi@gruppotriumph.it www.ercongressi.it AUSPICES S OCIETÀ I TALIANA DI E MATOLOGIA S OCIETÀ I TALIANA DI E MATOLOGIA S ...

Fusion of Lymphocytes and Myeloma Cells Procedure 1. Prepare a suspension of spleen cells in Hank's Balanced Salt Solution (HBSS), following the procedures in Preparation of Lymphocyte Cell Suspension , except resuspend the pellet of cells in 5ml of sterile DMEM without serum . 2. Prepare a suspension of myeloma cells as follows: a. Transfer a culture of myeloma cells from a large flask to a 50 ml sterile centrifuge tube (be sure to gently dislodge the myeloma cells from the bottom surface of the flask before transferring). b. Centrifuge for 4-5 minutes at 200 x g (setting of 3 on an IEC centrifuge). c. Discard the supernate. d. Add 5 ml of sterile DMEM without serum to the cell pellet. Resuspend the cells with a sterile pasteur pipette and sterile pipette bulb. 3. Determine the number of viable lymphocytes/ml ...

Fusion of B-lymphocytes and Myeloma Cells B-lymphocyte - produces antibodies, but cannot survive in tissue culture beyond 7-10 days myeloma cell - doesn't produce antibodies, but can survive in tissue culture "indefinitely" fusion combines these two characteristics into one cell (a "hybrid") B-lymphocyte (from spleen) + myeloma cell (from cultured cell line) add 50% polyethylene glycol (PEG) (fuses cell membranes) two separate nuclei in one cell membrane two nuclei will join (temporary tetraploid) chromosomes will mix together subsequent cell division (cells "return" to diploid nucleus) some "hybrids" will have the desired mix of chromosomes antibody specificity/antibody production + "immortality" in tissue culture optimum fusion procedure - favors production of desired hybrids cell ratio of 2 lymphocytes/1 myeloma cell (steps ...

haematologica 2004; 89(2):February 2004 174 [haematologica] 2004;89:174-182 T HERESE S TANDAL H ENRIK H JORTH -H ANSEN T HOMAS R ASMUSSEN I NGER M ARIE S. D AHL S TIG L ENHOFF A NNE -T OVE B RENNE C ARINA S EIDEL V ADIM B AYKOV A NDERS W AAGE M AGNE B ØRSET A NDERS S UNDAN Ø YVIND H JERTNER Osteopontin is an adhesive factor for myeloma cells and is ...

A Case-control Study of Multiple Myeloma in Decatur, Illinois Authors Celan J. Alo, M.D. Connie Austin, D.V.M., M.P.H., Ph.D. Holly L. Howe, Ph.D. Illinois Department of Public Health Page 2 Suggested Citation: Alo CJ, Austin C, Howe HL . A Case-control Study of Multiple Myeloma in Decatur, Illinois. Epidemiologic Report Series 97:3. Springfield, IL: Illinois Department of Public Health, February 1997. Copyright information: All material in this report is in the public domain and may be reproduced or copied without permission; citation is to source, however, is appreciated. Page 3 Abstract Background: A cancer cluster investigation that was conducted in ZIP code 62521 of the city of Decatur in Macon County, Illinois, showed a statistically significant excess of multiple myeloma cases ...

What is a Telephone Education Workshop? Cancer Care ’s free Telephone Education Workshops are educational seminars that are conducted over the phone. The workshops are a way for people from across the country and internationally to learn about cancer-related issues from the convenience of their home or office. Leading experts in oncology provide the most up-to-date information on the telephone. How do I participate? All you need is a telephone to participate in a Telephone Education Workshop. Participation is free, and no phone charges apply. How do I register? You may mail the registration form provided to Cancer Care or register online at www.cancercare.org. After you have registered, you will receive a packet of information and instructions. Emerging Therapies for Colorectal Cancer Friday March 5, 2004 1:30 - ...

Chapter 25: Myeloma 245 Myeloma 0\HORPD LV D UHODWLYHO\ UDUH IRUP RI FDQFHU DFFRXQWLQJ IRU OHVV WKDQ RI WKH FDQFHU EXUGHQ 7KH LQFLGHQFH UDWH RI P\HORPD KDV LQFUHDVHG E\ ±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

What you need to know Multiple Myeloma E ven though we hear about cancer almost every day, when you are diagnosed with cancer you may feel alone and afraid. You may also feel overwhelmed by all the information you are given and by the need to make so many decisions. This publication will give you and your family introductory information you need when you first learn that you have multiple myeloma ( myeloma ). It will help you gain a sense of control and help you work with your healthcare team to choose the best treatments for you. Let’s Make Cancer History 1 888 939–3333 | w w w . c a n c e r . c a | Forward > 526.PDF_Myeloma_final 12/4/01 11:51 AM Page 1 Page 2 What is cancer? Cancer is a disease that starts in our cells . Our bodies are made up of millions of ...

INTERNATIONAL MYELOMA FOUNDATION 2005 Brian D. Novis Research Award Senior Grant Application Applicant Name Page of _ SENIOR GRANT APPLICATION INTERNATIONAL MYELOMA FOUNDATION 2005 BRIAN D. NOVIS RESEARCH AWARD Provided by donations from private individuals The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma . This year’s awards will be in the amount of $80,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission ...

INTERNATIONAL MYELOMA FOUNDATION 2005 Brian D. Novis Research Award Junior Grant Application JUNIOR GRANT APPLICATION Provided by donations from private individuals The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma . This year's awards will be in the amount of $40,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward prevention and a cure. 1 Page 2 ...

completed - Abstracts (Scientific and Lay); Research Relevance. Page 2 completed - Biographical sketch for all key personnel. Page 3 completed - Budget. Page 4 completed - Budget justification. Page 5 completed - Research support (active and pending). Project Description (limited to ten (10) pages, not including references). Appendix (Clinical protocols, if applicable). Laboratory Animals Statement. Biohazards Statement. Four (4) sets of applicant's publications (if applicable). Each page must contain the applicant's full name in the top, right-hand corner. Applications submitted in English, single-spaced text, one-inch margins, and typed in either 10 pt. font Arial, 10 pt. font Courier or 12 pt. font Arial or 12 pt. font Times New Roman. Send the original + nine (9) double-sided copies to: Susie Novis, President 12650 ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Multiple Myeloma (MM) and Exposure to Ionizing Radiation 1 Multiple Myeloma (MM) and Exposure to Ionizing Radiation Summary : Studies conducted at the Los Alamos National Laboratory and other nuclear facilities, as well as those exposed to radiation from the atomic bomb suggest an increased likelihood of developing multiple myeloma for those who have been exposed to ionizing radiation. These findings are consistent with the determination of the National Research Council’s BEIR V committee that multiple myeloma has been associated with exposure to ionizing radiation. Multiple myeloma is a “specified” cancer under the EEOICPA. Historically, multiple myeloma incidence and mortality in Los Alamos County fall in the middle of New Mexico ...

©2003 Specialty Laboratories WO Multiple Myeloma 1/7/04 TN 1185 Multiple Myeloma Serum Free Light-chains Overview Clones of B cell lines (e.g., in multiple myeloma ) may produce homogeneous populations of kappa or lambda free light chain (FLC) molecules (historically called Bence Jones proteins when detected in urine specimens). Serum FLC can be used to identify and monitor patients with B-cell lineage tumors. They can also be used to characterize light chain amyloidosis. Urine is traditionally used for testing but needs to be concentrated and analyzed by protein electrophoresis (PE) or by immunofixation electrophoresis (IFE). 1 These techniques are often inadequate for accurate detection of FLC. Additionally, the amount of FLC in the urine is influenced by renal tubular function since normal kidneys are very efficient in preventing protein leakage from ...